Pharmaceutical terroir is the idea that the place, people, and/or process are locally distinct, and thus required for successful production. Ironically, while I would like to coin this term, I don’t actually believe pharmaceutical terroir exists in cell therapy. $LCTX
An opportunity to get involved with the OpRegen Machine Learning team: careers.gene.com/us/en/job/2… $LCTX
An excellent column on cell therapy manufacturing that aligns well with the Lineage “Better from the Beginning” approach to product development. $LCTX cellandgene.com/doc/combinat…
Just had a fun discussion on all things cell therapy with Ira, including a few bits on $LCTX; m.youtube.com/watch?v=fwBDF8….
Astellas data update at ARVO. +5 to +9 letters at 1yr. If you believe delivering a suspension of RPE can increase vision and improve anatomy in atrophic AMD, Lineage, Eyestem, Luxa, and Astellas are providing independent contributory evidence to that mechanism. $LCTX
Stopped for a pic at the Fischli and Weiss “Rock on top of Another Rock”, which evokes the beauty of pushing limits. An inspirational idea applicable to our regenerative medicine mission. Thanks for hosting us in Basel, Roche! $LCTX
Genuinely thrilled to have another prominent retina specialist getting involved with the OpRegen program! A big $LCTX welcome to @ArshadKhanani Director of Clinical Research at Sierra Eye Associates and his outstanding team! Up to 16 clinical sites now.
A message to current and prospective $LCTX shareholders: investor.lineagecell.com/new….
Please share. This will be an amazing opportunity for the right person. Join Lineage as the Head of Regenerative Medicine and become a pioneer in a new branch of medicine; non-oncology cell therapy. $LCTX lineagecell.com/company/care…
Why did we spend so many years investing in manufacturing? Because it doesn’t matter if you’re winning at halfway. Terrific article! $LCTX cellandgene.com/doc/why-do-s…
I’d like to send a warm welcome into the ongoing GAlette study of OpRegen cell therapy to sites #14 and #15 located in St. Petersburg FL and Bellaire TX. $LCTX
Despite disfavor among certain costly and/or commercially unmanufacturable CGT programs, it’s great to see rising support for “off the shelf” solutions in “non-cology” indications like GA. $LCTX tinyurl.com/Astellas-cell-th…
A massive Thank You to everyone who has played a role in our journey so far; patients, docs, employees, investors, advisors, and many more. $LCTX
All of us at $LCTX and CCN wish to express our gratitude to those who inspire us as #WeWorktoRestore - function, dignity, strength, clarity, independence, and hope.
@CEO_Culley #CellTherapy #ReplaceAndRestore #Careers
A warm welcome to Spokane Eye and Maryland Retina, two recent additions to the GAlette study of Lineage’s cell therapy program, OpRegen® for geographic atrophy. GAlette is now open at 13 clinical sites: clinicaltrials.gov/study/NCT… #genentech. $LCTX
Flying back to SAN today. Have been away from home 15 of the past 19 days. I appreciate my wife and kids being such great “behind the scenes” supporters of me and $LCTX!
We’re going “big game hunting” investor.lineagecell.com/new… $LCTX
Tracking only fast-growing GA patients can reduce the number of years needed to (maybe?) show vision preservation (btw, that’s years with a median patient age of 79), but your addressable population gets unavoidably smaller. Treat only the foveal-spared (30%) and forfeit 70% of the eligible. I suppose it makes sense if it opens the EU hubs.li/Q03FWY2l0. $LCTX
I didn’t know this was coming, but apparently called it correctly! reframe-ga.com/content/dam/u…



